To include your compound in the COVID-19 Resource Center, submit it here.

China's proposed annual NRDL revisions could increase pricing pressure

China's proposed guidelines regarding the annual revision of its National Drug Reimbursement List could increase pricing pressure for all included drugs.

Draft opinions released by China’s National Healthcare Security Administration (NHSA) Wednesday proposed extending price negotiations, adjustments or centralized procurement to all drugs on or seeking inclusion

Read the full 470 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE